English
GSK J4 HCl, CAS 1373423-53-0
GSK J4 HCl, CAS 1373423-53-0
Artikelnummer
BPS27627-2
Verpackungseinheit
50 mg
Hersteller
BPS Bioscience
Verfügbarkeit:
wird geladen...
Preis wird geladen...
Products from BPS Bioscience require a minimum order value above 400€
Background: GSK J4 is a potent cell-permeable inhibitor of the histone H3 lysine 27 (H3K27) demethylase JMJD3. GSK J4 is an ethyl ester derivative of GSK J1, a JMJD3 inhibitor (IC50= 60 nM) with restricted cellular permeability due to the highly polar carboxylate group, and rapidly hydrolyzed by macrophage esterase upon administration leading to the generation of pharmacologically relevant intracellular concentration of GSK-J1 . GSK J4 has been found to dose-dependently inhibit the production of tumor-necrosis factor-α (TNF-α), a LPS-driven cytokine involved in various fnflammatory disorders (IC50 = 9 µM).
Biological Activity: Inhibits JMJD3 and UTX with IC50 of 60 nM and inactive against a panel of demethylases of the JMJ family (IC50 value > 50 µM).
CAS Number: 1373423-53-0
Description: GSK J4 HCl is a cell permeable prodrug of GSK J1, which is the first selective inhibitor of the H3K27 histone demethylase JMJD3 and UTX with IC50 of 60 nM and inactive against a panel of demethylases of the JMJ family.
Purity: ≥98% by HPLC
Solubility: Soluble in DMSO 84 mg/ml, water 84 mg/ml, ethanol 84 mg/ml
Storage Stability: Store at or below -20°C. Solid form is stable at least 12 months from date of receipt, when stored as directed. Do not store aqueous solutions for more than one day.
Target: JMJD3, UTX
Biosafety Level: Not applicable (BSL-1)
References: Kruidenier L, et al. Nature. 2012 Aug 16;488(7411):404-8.
Background: GSK J4 is a potent cell-permeable inhibitor of the histone H3 lysine 27 (H3K27) demethylase JMJD3. GSK J4 is an ethyl ester derivative of GSK J1, a JMJD3 inhibitor (IC50= 60 nM) with restricted cellular permeability due to the highly polar carboxylate group, and rapidly hydrolyzed by macrophage esterase upon administration leading to the generation of pharmacologically relevant intracellular concentration of GSK-J1 . GSK J4 has been found to dose-dependently inhibit the production of tumor-necrosis factor-α (TNF-α), a LPS-driven cytokine involved in various fnflammatory disorders (IC50 = 9 µM).
Biological Activity: Inhibits JMJD3 and UTX with IC50 of 60 nM and inactive against a panel of demethylases of the JMJ family (IC50 value > 50 µM).
CAS Number: 1373423-53-0
Description: GSK J4 HCl is a cell permeable prodrug of GSK J1, which is the first selective inhibitor of the H3K27 histone demethylase JMJD3 and UTX with IC50 of 60 nM and inactive against a panel of demethylases of the JMJ family.
Purity: ≥98% by HPLC
Solubility: Soluble in DMSO 84 mg/ml, water 84 mg/ml, ethanol 84 mg/ml
Storage Stability: Store at or below -20°C. Solid form is stable at least 12 months from date of receipt, when stored as directed. Do not store aqueous solutions for more than one day.
Target: JMJD3, UTX
Biosafety Level: Not applicable (BSL-1)
References: Kruidenier L, et al. Nature. 2012 Aug 16;488(7411):404-8.
| Artikelnummer | BPS27627-2 |
|---|---|
| Hersteller | BPS Bioscience |
| Hersteller Artikelnummer | 27627-2 |
| Green Labware | Nein |
| Verpackungseinheit | 50 mg |
| Mengeneinheit | STK |
| Produktinformation (PDF) |
|
| MSDS (PDF) |
|
Immer für Sie da
Gernot Ensinger, M.Sc.
Laurent Haze
